Meaning a single design can lead to market-ready drugs for sale. This editorial explains how single-cell RNA-sequencing techniques may provide the lynchpin we’ve been looking for to explain spectrum of responses to immune checkpoint inhibition for what appear to be identical cancers—namely heterogeneous cellular ecosystems (e.g., immune cells, tumor stromal cells, etc) that make or break immunotherapeutic success. | Yofe, Nat Med 2020


Popular Posts